NCT02695290View on ClinicalTrials.gov

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

PHASE4TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 17, 2016

Primary Completion Date

August 26, 2016

Study Completion Date

August 26, 2016

Conditions
Carcinoma, Non-Small-Cell LungErbB Receptors
Interventions
DRUG

Afatinib

Trial Locations (1)

Unknown

1200.208.10032 Boehringer Ingelheim Investigational Site, Fountain Valley

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY